M3 muscarinic acetylcholine receptor facilitates the endocytosis of mu opioid receptor mediated by morphine independently of the formation of heteromeric complexes by Lopez-Gimenez, Juan et al.
  
 
 
 
 
Lopez-Gimenez, J., Alvarez-Curto, E., and Milligan, G. (2017) M3 muscarinic 
acetylcholine receptor facilitates the endocytosis of mu opioid receptor mediated by 
morphine independently of the formation of heteromeric complexes. Cellular Signalling, 
35, pp. 208-222. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/140300/ 
     
 
 
 
 
 
 
Deposited on: 8 May 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
M3 muscarinic acetylcholine receptor facilitates the endocytosis of 
mu opioid receptor mediated by morphine independently of the 
formation of heteromeric complexes. 
 
 
 
 
 
Juan F. Lopez-Gimenez1¶*, Elisa Alvarez-Curto2 and Graeme Milligan2 
 
 
1Institute of Biomedicine and Biotechnology of Cantabria, (IBBTEC), CSIC, Santander, 
Spain. 
 
2 Molecular Pharmacology Group, Institute of Molecular, Cell, and Systems Biology, College 
of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United 
Kingdom. 
 
¶ Present address: Center for Research in Molecular Medicine and Chronic Diseases 
(CIMUS), University of Santiago de Compostela (USC), Santiago de Compostela, Spain. 
 
 
 
 
*corresponding author: Juan F. Lopez-Gimenez  
CIMUS-USC. Av. Barcelona s/n. 15782 Santiago de Compostela. 
Spain. 
tel.: + 34 654356248 
email: jf.lopez.gimenez@csic.es 
 
 
 
 
 
 
 
 
 
 2 
Abstract 
Morphine inefficiency to induce the internalization of mu opioid (MOP) receptors observed 
in numerous experimental models constitutes a paradigm of G-protein coupled receptor 
(GPCR) functional selectivity. We recently described that activation of Gαq/11 proteins 
through 5-HT2A serotonin receptors co-expressed in the same cells facilitates MOP receptor 
endocytosis promoted by morphine. In order to explore whether a different Gαq/11 coupled 
GPCR would emulate this effect, a double stable Flp-In T-REx HEK293 cell line 
permanently expressing MOP-YFP receptors along with FLAG-M3-Cerulean receptors 
expressed in an inducible manner was generated. Fluorescence microscopy examination of 
these cells revealed a co-distribution of both receptors mainly compartmentalized in plasma 
membrane. Concurrent stimulation with carbachol and morphine promoted MOP receptor 
internalization, desensitization and down-regulation by morphine and this facilitation was not 
dependent on PKC activation. Co-immunoprecipitation experiments demonstrated that 
FLAG-M3-Cerulean/MOP-YFP receptors interact in heteromeric complexes in a time 
depending manner, i.e. the strongest interaction was detected after 96 hours of FLAG-M3-
Cerulean induced expression. Under these experimental conditions, treatment of cells with 
carbachol plus morphine resulted in the internalization of both receptors within separated 
endocytic vesicles as visualized by confocal microscopy. This trafficking segregation 
observed for FLAG-M3-Cerulean and MOP-YFP receptors upon agonist stimulation suggests 
that this protein-protein interaction presents temporal and dynamic properties. Moreover, 
MOP-YFP receptor internalization facilitated by FLAG-M3-Cerulean receptors is 
independent of the constitution of heteromeric complexes. 
Keywords: MOP receptor, M3 receptor, GPCR, morphine, Heteromerization, 
Endocytosis  
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1. Introduction 
The molecular pharmacology study of G-protein coupled receptors (GPCRs) during the last 
two decades has been principally focused on two aspects, namely receptor oligomerization 
and functional selectivity or biased agonism. The idea that family A receptors might 
constitute quaternary structures in form of dimer or higher order oligomers is widely accepted 
at the moment [1], although both the structural basis of the formation of such multiprotein 
arrangements and the functional consequences of these protein-protein interactions still 
constitute a topic of scientific investigation and debate [2]. This complexity in the receptor 
oligomeric organization escalates when considering the possibility of the formation of 
multimeric complexes constituted by different monomeric entities. In this sense and in 
general, homodimers seem to be the prevailing arrangement with the potential to form higher 
order oligomers, especially tetramers. However, in the case of heteromers, it is still obscure if 
such heterocomplexes are preferentially heterodimers or if they are mainly constituted by 
heteromers of homodimers [1]. On the other hand, the notion of functional selectivity refers to 
the property of some ligands to induce unique, ligand-specific receptor conformations that 
commonly can result in different activation of signal transduction pathways associated with 
that particular receptor. This differential activation might be expressed in differences in 
intrinsic activity and/or potency at one signalling pathway in relation to another that are not 
due to differences in affinity at the mediating receptor [3]. In fact, receptor oligomerization 
and functional selectivity are intimately related since the participation of monomeric units in 
heterocomplexes may confer novel properties to the agonist-directed trafficking of the 
signalling response mediated by those receptors. In relation to mu opioid (MOP) receptors, 
functional selectivity has been extensively described at different levels of their activity such 
as G-protein coupling, phosphorylation of intracellular domains, interactions with ß-arrestins, 
receptor desensitisation and internalisation [4]. Particularly in the case of MOP receptors, 
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there is a marked functional selectivity with regards the ability exhibited by some ligands to 
promote receptor internalization. In this sense, morphine constitutes one of the most 
paradigmatic models since it has been observed inefficacy to facilitate MOP receptor 
endocytosis in numerous cell systems when in fact it resulted competent in other biological 
responses mediated by the receptor activation and subsequent coupling to G-proteins in those 
same cells (for a review on this topic see [5]). Moreover, Whistler and collaborators propose a 
hypothesis asserting that the incapacity of morphine to endocytose MOP receptor after its 
activation constitutes the molecular basis of the development of tolerance to this opiate when 
used in prolonged treatments [6]. These authors went further on demonstrating that using 
morphine in combination with other opioids in such a way that the internalization of MOP 
receptors were promoted or by exchanging the C-terminus portion of MOP receptors by the 
equivalent domain from DOP receptors obtaining a chimeric receptor capable to endocytose 
with morphine, in both cases the validation of these results to physiological in vivo models 
resulted in a significant reduction of the development of tolerance to morphine in animals 
submitted to chronic treatments in nociception experiments [7-9]. Nevertheless, it is well 
accepted at the moment that tolerance is rather a multifaceted process involving multiple 
regulatory elements occurring both at the level of individual opioid-responsive cells and at the 
most complex level of neural circuits [10].  At the cellular level, and more particularly in 
heterologous expression models, there is evidence describing the overexpression of accessory 
proteins involved in the internalization/desensitization of receptors such as GRKs and ß-
arrestins as facilitators of MOP receptor endocytosis by morphine [11, 12]. In a similar way 
and more recently, we described that the co-activation of serotonin 5-HT2A receptors 
facilitated the desensitization, down-regulation and internalization of MOP receptors 
promoted by morphine when both receptors are co-expressed in Flp-In T-Rex 293 cells [13]. 
In relation to the facilitation of the endocytosis, that result was equivalently obtained with the 
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high homologous 5-HT2C receptor [14]. During the course of our studies with 5-HT2A 
receptors, we demonstrated that the inhibition of its coupling to Gαq/11 proteins by using the 
YM254890 compound aborted the facilitation of MOP receptor endocytosis by morphine 
[13]. In the present study we aimed to assess whether a different receptor coupled 
preferentially to Gαq/11 proteins would emulate the effect of the concomitant activation of 5-
HT2A receptor on desensitization, internalization and down-regulation of MOP receptors 
mediated by morphine. The receptor of choice for this purpose was the M3 muscarinic 
acethylcholine receptor, essentially because M3 is a family A GPCR that couples 
preferentially to Gαq/11 proteins and there are preliminary results supporting its co-expression 
with MOP receptors in neural tissue, particularly in the locus coeruleus [15-17]. In addition, a 
pharmacological interaction between both M3 and MOP receptors has been already described 
in that particular brain area in relation to the desensitization of MOP receptors mediated by 
M3 receptor activation [18, 19]. Our results herein indicate that M3 receptors when co-
activated might facilitate the internalization, desensitization and down-regulation of MOP 
receptors mediated by morphine in a manner that is independent of PKC activation. 
Furthermore, M3 and MOP receptors might interact to each other to form heterocomplexes 
that are not necessary for the pharmacological interaction between both receptors.  
 
 
2. Materials and Methods  
2.1. Materials 
All reagents for cell culture and Flp-InTM T-RExTM 293 cells were from Invitrogen (Paisley, 
UK). [3H]diprenorphine and [3H]QNB were from PerkinElmer Life and Analytical Sciences 
(Boston, MA). Doxycycline, carbachol, atropine, morphine, naloxone, DAMGO, Ro31-8220 
and chelerythrine were from SIGMA-Aldrich.  
 6 
2.2. Receptor Fusions with Fluorescent proteins 
Generation and subcloning of the human version of M3 muscarinic acetylcholine receptor 
construct was basically as described previously [20]. Briefly, the FLAG epitope tag was 
added at the amino terminus of the receptor by means PCR techniques using a forward primer 
containing the sequence of FLAG epitope (amino acid sequence DYKDDDDK). Afterwards, 
FLAG-M3 receptor was tagged at the carboxyl terminus with Cerulean fluorescent protein by 
amplifying the sequence corresponding to the receptor and removing the stop codon by PCR. 
The final product of this construction corresponds to a single open reading frame encoding for 
the receptor-fluorescent protein fusion. FLAG-M3-Cerulean was subcloned into the vector 
pcDNA5/FRT/TO (Invitrogen) for the subsequent generation of Flp-In T-REx HEK293 
inducible cell lines. MOP-YFP receptor [13] was obtained after amplification of human MOP 
receptor using PCR primers containing a SacI endonuclease site at the 5´end and an ApaI 
endonuclease site at the 3´end and removing in the process the stop codon. This PCR product 
was subsequently subcloned into peYFP-N1 vector resulting in a single open reading frame 
consisting of the MOP receptor with eYFP fused to the carboxyl terminus.  All these 
constructs were verified by DNA sequencing. 
 
2.3. Generation of Stable Flp-In T-REx HEK293 Cell Lines   
 In order to generate Flp-In T-REx HEK293 cell lines able to express FLAG-M3-Cerulean 
receptors in an inducible manner we followed the detailed protocol described elsewhere [21]. 
Briefly, cells were transfected with a mixture containing the FLAG-M3-Cerulean receptor 
cDNA into pcDNA5/FRT/TO vector and pOG44 vector in a ratio 1:9 using Effectene 
transfection reagent (QIAGEN, Hilden, Germany) according to the manufacturer´s 
instructions. When cotransfected with pcDNA5/FRT plasmid into the Flp-In mammalian host 
cell line, the Flp recombinase expressed from pOG44 mediates integration of the 
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pcDNA5/FRT vector containing the gene of interest into the genome via Flp recombination 
target (FRT) sites. Cell maintenance and selection were as described previously [22]. Clones 
resistant to blasticidin were screened for FLAG-M3-Cerulean espression by both fluorescence 
presence and Western blotting. Cells were treated with varying concentrations of doxycycline 
for different periods in order to induce expression of FLAG-M3-Cerulean receptors. The 
optimal expression was achieved after 24 hours of treatment with 0.01 µg of doxycycline/ml 
growth medium (see Results). A double stable cell line expressing MOP-eYFP constitutively 
and FLAG-M3-Cerulean in an inducible manner was generated from the Flp-In T-REx 
HEK293 cells described above. Cells were transfected using Effectene (QIAGEN) with the 
vector containing MOP-YFP. After transfection, cells were selected for resistance to 
Geneticin (G418; 1mg/ml), and the resistant clones were screened for receptor expression by 
fluorescence microscopy. 
 
2.4. Living Cell Epifluorescence Microscopy 
Cells expressing receptors tagged with Cerulean or eYFP were grown onto poly-lysine-treated 
coverslips. These coverslips were placed into a microscope chamber containing physiological 
saline solution (130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1mM MgCl2, 20 mM HEPES, and 
10 mM D-glucose, pH 7.4). Cell fluorescent images were acquired using a TE2000-E inverted 
microscope (Nikon, Melville, NY) equipped with a 40X (numerical aperture, 1.3) oil 
immersion Plan Fluor lens and a cooled digital CoolSNAPHQ charge-coupled device camera 
(Photometrics, Tucson, AZ). For internalisation experiments in real time, drugs diluted in 
physiological saline solution were perfused into the microscope chamber and pictures were 
taken every 3 minutes during a period of 30 to 35 minutes.  
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2.5. Cell Membrane Preparation 
Harvested pellets from Flp-In T-REx HEK293 cells kept at -80ºC were thawed and 
resuspended in 10 mM Tris and 0.1 mM EDTA, pH 7.4 (Tris/EDTA buffer). Cells were 
homogenised by 25 passes of a glass-on-Teflon homogeniser. The resulting suspension was 
centrifuged at 1200g for 10 min to remove cellular debris and nuclei. The supernantant was 
subsequently centrifuged at 218,000g for 30 min in an Optima TLX ultracentrifuge (Beckman 
Coulter, Fullerton, CA). Resulting pellets were resuspended in Tris/EDTA buffer and passed 
through a 25-gauge needle. Protein concentration was determined and the membranes were 
stored at -80ºC until use.  
 
2.6. Radioligand Binding Assays 
[3H]QNB Binding. Saturation binding curves were initiated by the addition of 1 μg of 
membrane protein to assay buffer (20 mm HEPES, 100 mm NaCl, and 10 mm MgCl2, pH 7.4) 
containing varying concentrations of [3H]QNB (50.5 Ci/mmol), i.e. nine points ranged from 
0.01 nM to 0.45 nM. Nonspecific binding was determined in the presence of 10 μm atropine. 
Every point was performed in triplicate. Reactions were incubated for 90 min at 25 °C, and 
bound ligand was separated from free by vacuum filtration through GF/C filters (Brandel Inc., 
Gaithersburg, MD). The filters were washed twice with assay buffer, and bound ligand was 
estimated by liquid scintillation spectrometry. 
 
2.7. [3H]Diprenorphine Binding. Cell membranes (15-20 μg of protein) were incubated with 
[3H]diprenorphine (0.02-2 nM in saturation assays; 1-2 nM in single point assays) in a total 
volume of 1 ml of buffer (50 mM Tris-HCl, 1 mM EDTA, and 10 mM MgCl2, pH 7.4). 
Nonspecific binding was determined by the inclusion of 100 μM naloxone. Every point was 
performed in triplicate. Binding was initiated by the addition of membranes, and the tubes 
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were incubated at 25°C for 60 min. The assay was terminated by rapid filtration using a cell 
harvester (Brandel Inc.) with three 5-ml washes of ice-cold phosphate-buffered saline. The 
filters were soaked in 3 ml of scintillation fluid, and radioactivity was determined by liquid 
scintillation spectrometry. 
 
2.8. [Ca2+]i Measurements 
Cells were seeded into 96-well plates, loaded with the Ca2+-sensitive dye FURA-2 
acetoxymethyl ester (1.5 µM) by incubation (30 min; 37ºC) under reduced light in DMEM 
medium. Calcium imaging and analysis were then performed using a FLEXstation (Molecular 
Devices, Sunnyvale, CA). 
 
2.9. IP-1 Accumulation Measurements 
Cells expressing receptors tagged with Cerulean and eYFP were either induced for 24 hours 
with 10 ng.mL-1 of doxycycline or left untreated. Cells were harvested using Versene 
dissociation reagent, washed, resuspended in Hank’s Buffered Salt Solution (HBSS) and 
subsequently added to 384-well low volume Optiplates to a final cell density of 9800 
cells/well. Cells were stimulated with variable concentrations of carbachol for 30 min at 37oC. 
Detection of IP-1 accumulation was carried out for 1 hour at room temperature and protected 
form the light, using the IP-One Tb kit (Cisbio Bioassays, Bagnols-sur-Cèze, France) 
according to the manufacture’s instructions. Plates were read using a PheraStar FS (BMG 
Labtechnologies, Offenburg, Germany).  
 
2.10. Western Blotting 
Samples were heated at 65ºC for 14 min and subjected to SDS-polyacrylamide gel 
electrophoresis analysis using 4 to 12% bis-Tris gels (NuPAGE, Invitrogen) and MOPS 
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buffer. After electrophoresis, proteins were transferred onto nitrocellulose membranes that 
were incubated in a solution of 5% non-fat milk and 0.1% Tween-20 in Tris-buffered saline at 
room temperature on a rotating shaker for 2 hours to block nonspecific binding sites. 
Afterwards, membranes were incubated overnight with a rabbit anti-FLAG polyclonal 
antibody (SIGMA-Aldrich) or a sheep anti-MOP antiserum generated in house [22]. Protein 
antibody interactions were detected using horseradish peroxidise-linked anti-rabbit IgG or 
anti-goat IgG secondary antisera (GE Healthcare, Chaltfont St. Giles, Buckinghamshire, UK). 
Immunoblots were developed by application of enhanced chemiluminescence solution (ECL, 
Pierce Chemical Rockford, IL). 
 
2.11. Biotinylation Protection Assay 
Cells growing on culture dishes were treated with 0.3 mg/ml disulfide-cleavable biotin (Pierce 
Chemical Rockford, IL) in phosphate buffered saline (PBS) at 4ºC for 30 min. After washing 
with fresh PBS, cells were pre-treated with warmed growth medium (37ºC) for 15 min. 
Afterwards, cells were treated with drugs during at least 30 min to promote receptor 
endocytosis and meanwhile the cells corresponding to either 100% of biotinylation as 
stripping control were kept at 4ºC in PBS. After agonist treatment, cells were washed with 
PBS at 4ºC and the biotinylated receptors were stripped with a buffer containing 50 mM 
glutathione, 0.3 M NaCl, 75 mM NaOH and 1 % FBS. Samples were then washed with PBS 
at 4ºC and cell extracts were made in 0.1% Triton X-100, 150 mM NaCl, 25mM KCl and 10 
mM Tris-HCl (pH 7.4). Cellular debris was removed by centrifugation at 10,000g x 10 min at 
4ºC and cell lysates were immunoprecipitated with immobilised Neutravidin protein (Pierce 
Chemical Rockford, IL) for at least 1 hour at 4ºC. After washing with fresh lysis buffer, 
samples were processed for Western Blotting. 
 
 11 
2.12. Co-Immunoprecipitation Assay 
Harvested cells were resuspended in RIPA buffer (50 mM HEPES, 150 mM NaCl, 0.5% 
sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 10 mM NaF, 5 mM EDTA, 0.1 mM 
NaPO4, 5% ethylene glycol) containing Complete protease inhibitors mixture (Roche 
Diagnostics). Cells were placed on a rotating wheel for 1 h at 4 °C. Samples were then 
centrifuged for 1h at 100,000 x g at 4 °C, and the supernatant was transferred to a fresh tube 
containing 50 µl of protein G beads (Sigma) to pre-clear the samples. Following incubation on 
a rotating wheel for 1 h at 4 °C, the samples were re-centrifuged at 20,800 x g at 4 °C for 1 
min, and the protein concentration of the supernatant was determined. Samples containing 
equal protein amounts were incubated overnight with 40 µl of protein G beads and the 
immunoprecipitating antibody (2 µl of sheep anti-MOP) at 4 °C on a rotating wheel, and 
fractions were reserved to monitor protein expression in the cell lysates. Samples were 
centrifuged at 20,800 x g for 1 min at 4 °C, and the protein G beads were washed three times 
with RIPA buffer. Afterwards samples were processed for Western Blotting.  
 
2.13. Co-localization Studies by Confocal Microscopy 
Flp-In T-REx HEK293 cells expressing both FLAG-M3-Cerulean and MOP-eYFP receptors 
were submitted to the different agonist treatments during 30 min at 37 C and subsequently 
they were fixed with 4% paraformaldehyde solution in PBS for 10 minutes at room 
temperature. After fixation, cells were rinsed with PBS at room temperature, mounted onto 
slides and kept until confocal microscopy examination. Confocal images, (512x512 pixels; 
0.07mm pixel size) were acquired sequentially on a SP5 laser-scan microscope  (Leica) with a 
63x 1.4 NA objective, a 2 Airy Units pinhole, x7 electronic zoom and 400Hz speed using 
LAS AF acquisition software. Cells were excited sequentially with 458nm and 514nm laser 
lines and emission captured between 465-500nm (CFP) and 525-575nm (YFP). Images are 
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presented after digital adjustment of contrast to maximize signal with ImageJ software. In all 
cases, exposure time, sensor gain, and digital manipulation were the same for control and 
experimental samples. Co-localization analysis was carried out with ImageJ software by using 
the JACoP plugging described elsewhere [23]. Particularly, Pearson´s correlation coefficient 
was used to compare the overlapping degree between images obtained with the different 
fluorophore light settings. 
 
2.14. Quantitative Analysis of Endocytosis by Epifluorescence Microscopy 
Flp-In T-REx HEK293 cells permanently expressing MOP-YFP receptors and treated at 
different time points from 24 hours to 120 hours with doxycycline (10 ng.mL-1) to induce the 
expression of FLAG-M3-Cerulean receptors were grown on poly-d-lysine-treated coverslips. 
Coverslips were placed into a microscope chamber containing physiological saline solution 
(130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1mM MgCl2, 20 mM HEPES, and 10 mM D-
glucose, pH 7.4). To conduct internalisation experiments in real time, drugs were diluted in 
physiological saline solution and perfused into the microscope chamber and 15 planes of 0.49 
m Z-step size were acquired for 15 minutes at a rate of 1 frame per minute in an inverted 
epifluorescence microscope (AF6500; Leica Microsystems) equipped with temperature 
control (PeCon GmbH) at 37 C. Cell fluorescence was visualized with a 63x 1.3 NA oil 
objective, 470/40 excitation and 515LP emission filters, and images (1004x1002 pixels; 0.13 
m pixel size) were acquired with a DU8285_VP (Andor Technology) camera using 
exposures of 200 ms or less and an EM Gain of 20. Images were subsequently analysed with 
the Q_Endosomes algorithm previously described [14] by using ImageJ and Matlab software. 
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2.15. Data Analysis 
Data were analyzed using Prism (GraphPad Software Inc., San Diego, CA), and statistical 
significance was determined using either Student's t test or one-way/two-way ANOVA 
followed by the post hoc analysis as appropriate. P < 0.05 determined statistical significance. 
This study is essentially exploratory, therefore statistics analysis is descriptive only. When not 
indicated, error bars correspond to standard deviation (SD). 
 
3. Results 
 
3.1. Generation and characterization of a Flp-In T-Rex 293 cell line harbouring the M3 
receptor at the inducible locus and constitutively expressing the MOP receptor  
An example of a clone from the cell line generated as described in Methods section is shown 
in Figure 1A. Both in the absence and presence of doxycycline YFP fluorescence 
corresponding to MOP-YFP was present and largely at the surface of cells, whilst CFP 
fluorescence corresponding to FLAG-M3-Cerulean was observed only following treatment 
with doxycycline (Figure 1A). Addition of varying concentrations of doxycycline to these 
cells followed by immunoblotting of SDS-PAGE resolved membranes revealed 
concentration-dependent expression of FLAG-M3-Cerulean (Figure 1B), with maximal 
expression produced by some 10 ng.mL-1 doxycycline. Equivalent immunoblots with an anti-
MOP receptor antibody confirmed constitutive expression of MOP-YFP and that this was 
apparently unaltered by the induced expression of FLAG-M3-Cerulean (Figure 1B). 
Following addition of doxycycline expression of FLAG-M3-Cerulean could be detected 
within 24 hours and over longer time periods expression levels continued to increase 
gradually (Figure 2).  Details of the expression levels of the two receptors were obtained via 
[3H]ligand binding studies. Saturation binding studies performed with the muscarinic 
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antagonist [3H]QNB on membranes from cells induced with 10 ng.mL-1 doxycycline for 24h 
identified a single saturable binding site of 4125 +/- 591 fmol/mg protein and an affinity 
constant (Kd) of 0.087 ± 0.01 nM (means +/- SEMs,  n = 5) (Figure 3A). Equivalent 
experiments performed with samples from uninduced cells generated a Bmax of 430 fmol/mg 
protein. These sites are likely to represent endogenously expressed muscarinic receptors [24] 
as neither imaging for CFP nor anti-FLAG immunoblots suggested leak of expression of 
FLAG-M3-Cerulean in the absence of doxycycline (Figure 1). Levels of MOP-YFP were 
assessed via saturation [3H]diprenorphine binding assays. In the absence of doxycycline 
treatment a single saturable specific binding site corresponding to 1374 ± 215 fmol/mg 
protein with Kd = 0.24 ± 0.02 nM (n=5) was observed.  Following doxycycline treatment the 
level of MOP-eYFP increased (t-test P = 0.0321) to 2345 ± 307 fmol/mg membrane protein (n 
= 5) with a modest decrease (t-test P = 0.1962), Kd = 0.37 ± 0.09 nM, in affinity for this 
ligand (Figure 3B).  
The muscarinic M3 receptor couples preferentially to heterotrimeric Gαq/11 proteins and this 
results in mobilization of intracellular calcium. Initial downstream signalling from the 
activation of Gαq/11 proteins leads to phospholipase C activation and the production of inositol 
1, 4, 5-tri-phosphate (IP3) and diacylglicerol. We measured this pathway in cells co-
expressing FLAG-M3-Cerulean and MOP-YFP initially by recording the accumulation of 
myo-inositol 1-phosphate, a product of IP3 degradation, after agonist treatment. In 
doxycycline-induced cells the muscarinic agonist carbachol elicits a substantial response 
(pEC50 = 5.80 ± 0.24, mean +/- SEM, n = 3) (Figure 3C), that is greatly reduced in the un-
induced cells (pEC50 = 3.64 ± 0.07, mean +/- SEM, n = 3) (Figure 3C). Measurement of 
further downstream signalling by means of monitoring intracellular calcium ([Ca2+]i) release 
shows that carbachol potently elevates [Ca2+]i in doxycycline-induced cells (pEC50 = 7.95 ± 
0.05, mean +/- SEM, n = 3). However, consistent with the endogenous expression of a 
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muscarinic receptor population, carbachol also elevated [Ca2+]i in uninduced cells but with 
substantially lower potency (pEC50 = 5.69 ± 0.08, n = 3) (Figure 3D).  
 
3.2. Desensitization and internalization studies on MOP-YFP receptors 
Cells induced to express FLAG-M3-Cerulean were treated at varying times with either 
morphine (1 µM), carbachol (1 mM) or concurrently with a combination of morphine and 
carbachol. Following removal of the ligands, membranes prepared from these cells were 
employed in [35S]GTPγS binding assays to assess activation of Gi-family G-protein in 
response to varying concentrations of morphine. Pre-treatment with morphine for up to 4 
hours did not alter the apparent efficacy or potency of morphine (Figure 4A, Table 1). This 
was also the case after pre-treatment with carbachol (Figure 4B, Table 1). In contrast, 
concurrent treatment with morphine plus carbachol caused a marked reduction in the potency 
of morphine (Figure 4C, Table 1) that was maximal within 30 minutes and maintained at 
longer times of pre-treatment. This effect was also observed in relation to the efficacy of 
morphine, particularly within the first 60 min of pre-treatment (Figure 4C, Table 1). In many 
circumstances sustained treatment with morphine fails to cause down-regulation of the MOP 
receptor. Indeed, in cells induced to co-express FLAG-M3-Cerulean and MOP-eYFP, 
treatment with morphine for up to 4 hours did not result in a downregulation of MOP-YFP 
levels (Figure 4D). By contrast treatment with the combination of morphine and carbachol 
did cause loss of some 30% of the [3H]diprenorphine binding sites and this reached maximal 
levels within a 2 hour treatment period (Figure 4D).  
Morphine also failed to produce internalization of MOP-YFP from the surface of cells, 
whether MOP-YFP was expressed in the absence (data not shown) or the presence (Figure 
5) of FLAG-M3-Cerulean. By contrast, and as noted previously in such transfected Flp-In T-
Rex 293 cells [13], DAMGO produced extensive internalization of MOP-YFP in both 
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situations (Figure 5) but did not cause detectable internalization of FLAG-M3-Cerulean when 
the two receptors were co-expressed. Carbachol was also unable to cause internalization of 
MOP-YFP when cells were induced to co-express the two receptors and, indeed had little 
capacity to cause internalization of FLAG-M3-Cerulean in these studies (Figure 5). However, 
as anticipated from the down-regulation studies, co-addition of carbachol and morphine 
resulted in internalization of MOP-YFP in cells induced to co-express the two receptors 
(Figure 5), although this still did not result in substantial internalization of FLAG-M3-
Cerulean (Figure 5). 
Such imaging studies can be subjective, depending on the field of cells examined, and are 
challenging to quantitate adequately. As such we approached a cell population analysis of 
ligand effects via a series of cell surface biotinylation studies (Figure 6). In cells induced to 
co-express the two receptors cell surface proteins were biotinylated and following challenge 
with various ligand combinations for 30 min the biotin was cleaved from proteins remaining 
at the cell surface. Those proteins that had become internalized were ‘protected’ from removal 
of the biotin and after capture by streptavidin were resolved by SDS-PAGE and detected by 
immunoblotting. Treatment with each of DAMGO, morphine or carbachol alone did not 
increase the ‘protected’ form of FLAG-M3-Cerulean as detected by anti-FLAG 
immunoblotting (Figure 6A), whilst any increase in internalization of FLAG-M3-Cerulean 
produced by combinations of carbachol with either DAMGO or morphine failed to reach 
statistically significant levels (Figure 6A). By contrast, in anti-MOP receptor immunoblots 
although neither morphine nor carbachol in isolation produced internalization of MOP-YFP 
compared to vehicle (Figure 6B), as expected, DAMGO generated strong internalization 
(Figure 6B). Although the effect of DAMGO was not enhanced with co-addition of carbachol 
(Figure 6B), the co-addition of morphine and carbachol also resulted in substantial 
internalization (Figure 6B). 
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Phorbol myristate acetate (PMA) is a broad spectrum activator of protein kinase C isoforms. 
As such we assessed whether direct activation of protein kinase C would mimic the effect of 
carbachol. Regardless the induction of FLAG-M3-Cerulean expression, addition of a 
combination of morphine and PMA (0.1 µM) was unable to enhance internalization of MOP-
YFP to levels beyond those produced by morphine alone (Figure 7). Epifluorescence 
microscopy experiments conducted with cells expressing both receptors confirmed these 
results observed in biotinylation protection assays, i.e. morphine plus PMA treatment do not 
promote MOP-YFP receptor endocytosis (Figure 8A). Previous studies on the facilitation of 
MOP-YFP receptor internalisation by co-activation of 5-HT2A receptors demonstrated the 
participation of PKC in this process by preventing this effect upon treatment with selective 
inhibitors of this kinase. Equivalent experiments were performed with cells co-expressing 
FLAG-M3-Cerulean and MOP-YFP receptors (Figure 8B and 8C); in this case, neither 
Ro31-8220 (0.1 µM) nor chelerytrine (1 µM) significantly inhibited MOP-YFP receptor 
internalisation promoted by morphine plus carbachol treatment.  
 
3.3 MOP and M3 receptor interaction studies 
Epifluorescence microsocopy images obtained from cells expressing MOP-YFP and FLAG-
M3-Cerulean receptors after 24 hours of doxycycline induction revealed a co-distribution of 
both receptors in those cell compartments where they are expressed, principally in the plasma 
membrane. This cellular co-localisation prompted us to further investigate whether MOP and 
M3 are interacting to each other constituting receptor heterocomplexes. Co-
immunoprecipitation experiments were conducted by using anti-MOP receptor as 
immunoprecipitating antibody in cell lysates in order to acquire samples enriched in MOP-
YFP receptors. Subsequently, these samples were subjected to SDS-PAGE electrophoresis 
and the resulted immunoblots processed with anti-FLAG antibody. As anticipated, samples 
 18 
from cells not treated with doxycycline and therefore not expressing FLAG-M3-Cerulean 
receptors resulted in a complete absence of specific immunoreactivity signal at the expected 
size for FLAG-M3-Cerulean receptor (Figure 9A, lane Ø) excluding then the possibility of 
any artifactual result. However, similar results were observed after 24 hours of doxycycline 
induction, i.e. no specific signal was observed in blots corresponding to immunoprecipitated 
samples obtained from cells co-expressing both receptors (Figure 9 A, lane 24). The presence 
of MOP-YFP and FLAG-M3-Cerulean receptors in these samples was controlled by analysing 
the specific immunoreactivity of MOP and FLAG antibodies in blots obtained from cell 
lysates prior to immunoprecipitation (Figure 9 A, lower panels). Doxycycline time-course 
experiments were carried out in order to evaluate the potential effect of the inducible receptor 
(FLAG-M3-Cerulean) period of expression on the formation of heterocomplexes with the 
constitutively expressed receptor (MOP-YFP). Indeed, upon 96 hours of doxycycline 
treatment a clear and specific band corresponding to FLAG-M3-Cerulean size was observed in 
blots obtained from immunoprecipitated samples (Figure 9A, lane 96). Internalisation 
experiments conducted by both fluorescence microscopy and biotinylation protection assay 
(Figures 5 and 6 respectively) showed that MOP-YFP receptor endocytosis was not 
accompanied by FLAG-M3-Cerulean receptor either after stimulation of MOP receptors 
alone, i.e. DAMGO treatment or both receptors concurrently, i.e. DAMGO plus carbachol and 
morphine plus carbachol treatments. Cells used for those experiments were induced for 24 
hours with doxycycline to get FLAG-M3-Cerulean receptors expressed and as described 
above at this time point there is not an interaction between both receptors. Therefore, cells 
induced to express FLAG-M3-Cerulean receptors for up to 96 hours were treated during 30 
minutes with these drugs that promote MOP-YFP receptor internalisation, i.e. DAMGO, 
DAMGO plus carbachol and morphine plus carbachol as well as vehicle as a control. After 
treatments, cell lysates were obtained to be immunoprecipitated with anti-MOP antibody and 
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subsequently processed by Western blotting with anti-FLAG antibody (Figure 9B). Blots 
obtained with immunoprecipitates showed a specific band corresponding to FLAG-M3-
Cerulean receptors in the four experimental conditions considered, although the signal was 
substantially weaker in samples originated from cells treated with DAMGO alone (Figure 9B, 
lane D). The reason of that divergence was not possible disparities in the expression levels of 
both receptors among the different treatment groups since immunoblots obtained with cell 
lysates prior to immunprecipitation showed no substantial differences in signals obtained with 
either anti-FLAG as anti-MOP antibodies (Figure 9B, lower panels). Equivalent experiments 
were conducted in parallel by fluorescence microscopy to evaluate the endocytosis of both 
receptors under these experimental conditions. After 30 minutes of treatment, vehicle cells 
show both receptors predominantly at the plasma membrane (Figure 9C, Ø); in contrast, 
MOP-YFP receptors in cells treated with DAMGO presented a robust internalisation whereas 
FLAG-M3-Cerulean receptors remained at the cell surface (Figure 9C, D). Finally, 
concurrent treatment using either DAMGO plus carbachol as morphine plus carbachol, 
resulted in the formation of endocytosis vesicles for both receptors (Figure 9C, DC and 
MC).  A detailed observation of the microscopy fluorescence images corresponding to these 
experimental conditions where both FLAG-M3-Cerulean and MOP-YFP receptors 
endocytosed indicates that the majority of vesicles containing either receptor do not coincide 
spatially in intracellular compartments (Figure 9C, DC and MC). In order to further explore 
more accurately this issue, co-localization analysis of both fluorescent signals were conducted 
by confocal microscopy in cells induced to express FLAG-M3-Cerulean receptors with 
doxycycline for either 24 or 96 hours and subsequently treated with combinations of DAMGO 
plus carbachol or morphine plus carbachol to promote the internalization of both co-expressed 
receptors. As already observed in biotinylation protection assays (Figure 6), both agonist 
combinations resulted in a robust internalization of MOP-YFP receptors visualized as a YFP 
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fluorescent signal in form of punctuate vesicles distributed throughout plasma membrane and 
cytosolic structures in cells treated for 24 hours with doxycycline to induce the expression of 
FLAG-M3-Cerulean receptors (Figure 10, 24 hours DOX, DC and MC). Equivalent 
microscopic fields illuminated to make visible FLAG-M3-Cerulean receptors display a 
fluorescent signal distribution substantially divergent, particularly in intracellular 
compartments where the presence of FLAG-M3-Cerulean receptors in form of endocytic 
vesicles are notably reduced in comparison to MOP-YFP receptors (Figure 10, 24 hours 
DOX, DC and MC).  Pearson´s correlation analysis to determine the co-localization degree 
between both Cerulean and YFP images resulted in reduced coefficient values in selected 
cytosolic regions of cells treated with DAMGO plus carbachol and morphine plus carbachol, 
i.e. r = 0.223 and r = 0.248 respectively (Figure 10, 24 hours DOX, DC and MC). On the 
other hand, coefficient correlation values obtained in cellular regions corresponding to the 
plasma membrane from the same microscopic fields resulted markedly higher, r = 0.642 and r 
= 0.579 respectively, and comparable to the one determined in the plasma membrane of 
control cells treated with vehicle, i.e. r = 0.654 (Figure 10, 24 hours DOX). Paralleled 
experiments were carried out with cells induced to express FLAG-M3-Cerulean receptors for 
96 hours (Figure 10, 96 hours DOX); under these experimental conditions, treatment with 
either DAMGO or morphine both of them in combination with carbachol for 30 minutes led 
to FLAG-M3-Cerulean and MOP-YFP receptor internalization (Figure 9C, DC and MC), 
being in this case FLAG-M3-Cerulean receptor endocytosis more manifest in concofocal 
microscopy images than in equivalent conditions from cells treated with doxycycline for 24 
hours (Figure 10, 24 hours and 96 hours, DC and MC). However, although the presence of 
FLAG-M3-Cerulean receptor in cytosolic compartments in form of punctuate structures was 
at a similar extent of the ones observed for MOP-YFP receptors, both fluorescent signal 
distributions were predominantly different when overlapping selected regions from the same 
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microscopy field (Figure 10, 96 hours, DC and MC). The correlation coefficients obtained 
from images including endocytic vesicles corresponding to both receptors in cells treated 
either with DAMGO plus carbachol or morphine plus carbachol were r = 0.368 and r = 0.372 
respectively. These coefficient values were substantially lower than the ones determined in 
areas corresponding to the plasma membrane from the same cells, i.e. r = 0.731 and r = 0.719 
respectively, that were comparable to the correlation coefficient observed in the plasma 
membrane of control cells treated with vehicle, i.e. r = 0.764 (Figure 10, 96 hours, DC and 
MC). Therefore, these data indicate that after 96 hours of doxycycline treatment FLAG-M3-
Cerulean and MOP-YFP receptors co-localize essentially at the plasma membrane level where 
their concurrent activation by selective agonists, i.e. DAMGO or morphine in combination 
with carbachol, led to their simultaneous internalization predominantly within separate 
endocytic vesicles. 
 
3.4. Quantitative analysis of MOP-YFP receptor endocytosis by fluorescence microscopy 
in living cells 
The formation of endocytic vesicles upon receptor activation by agonist compounds 
constitutes a biological response susceptible to be measured and evaluated in terms of the 
magnitude, i.e. number of endosomes, as well as the kinetics of this process, i.e. half time to 
reach the maximal effect. We have recently developed an image analysis tool to quantitatively 
assess MOP-YFP receptor internalization following agonist stimulation in images obtained 
from living cells by fluorescence microscopy [14]. In order to investigate the potential effect 
of FLAG-M3-Cerulean and MOP-YFP receptor interactions on MOP-YFP receptor 
endocytosis promoted by agonists, cells were treated with doxycycline for different periods 
ranging from 24 to 120 hours with an interval of 24 hours between each time point. 
Afterwards, cells were treated with DAMGO or morphine plus carbachol during 15 minutes 
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and images from different planes through the Z-axis were acquired at 1-minute intervals. 
Cells not treated with doxycycline, and therefore not expressing FLAG-M3-Cerulean 
receptors, exhibited MOP-YFP receptor endocytosis when challenged with either DAMGO or 
combined morphine plus carbachol, evidencing that the involvement of M3 receptors 
endogenously expressed in Flp-In T-Rex 293 is sufficient to facilitate MOP-YFP receptor 
internalization by morphine (Table 2). When comparing the endocytosis response elicited by 
M3 and MOP-YFP receptor co-activation with the equivalent one observed upon direct 
activation of MOP-YFP receptor with DAMGO, morphine plus carbachol response resulted 
significantly lower (17.82  2.79 versus 35.11  3.88 vesicles per cell, t-test P=0.024) and less 
rapid endocytosis (7.72  0.69 versus 4.40  0.32 half time in minutes, t-test P=0.012) (Table 
2). On the other hand and regardless the period of doxycycline treatment to induce its 
expression, the presence of FLAG-M3-Cerulean receptor did not significantly modify MOP-
YFP receptor endocytosis parameters observed in morphine plus carbachol treatments in 
terms of efficiency and half time to reach this maximal response (Table 2). In a different 
manner, co-expression with FLAG-M3-Cerulean resulted in a significant reduction of the 
maximal response in form of number of vesicles per cell containing MOP-YFP receptors upon 
treatment with DAMGO being the magnitude of this reduction similar across the different 
time points of doxycycline treatment (Table 2). However, this effect of FLAG-M3-Cerulean 
receptors on the maximal endocytic response of MOP-YFP receptor elicited by DAMGO was 
not accompanied by a significant change in the kinetic properties of the process (Table 2).  
 
4. Discussion 
Previous investigations on different molecular pharmacology aspects of MOP receptors 
conducted in heterologous expression models have revealed an evident functional selectivity 
in relation to the initiation of endocytosis processes in response to agonist binding [4]. In this 
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sense, morphine constitutes one of the most paradigmatic examples due to its inability to 
promote MOP receptor internalisation in the majority of the cellular expression systems 
where it has been assayed [5]. However, this lack of efficacy in promoting receptor 
internalisation is not accompanied by an equivalent deficiency in other functional responses, 
i.e. coupling to Gi/o proteins, assessed by intracellular second messenger determinations such 
as cyclic AMP levels or incorporation of radioactive non-hydrolysable forms of guanine 
nucleotides (GTPS). Although the molecular and cellular mechanisms underlying the 
disparity observed for morphine when compared to other MOP receptor agonists are not 
completely elucidated, substantial efforts and advances have been achieved during the last 
years to solve this scientific question [10]. Actually, the inability of morphine to endocytose 
MOP receptors upon activation may be overcome since under particular circumstances the 
internalisation of MOP receptors by morphine is possible, essentially by overexpression of 
accessory proteins involved in G-protein coupled receptor endocytosis mediated by agonist 
binding, principally GRK2 and -arrestin2 among others [5, 11, 12]. We recently described 
that the co-activation of either 5-HT2A or 5-HT2C serotonin receptor subtypes facilitates the 
endocytosis of MOP receptors promoted by morphine when co-expressed in Flp-InTM T-
RExTM 293 cells [13, 14]. In the case of 5-HT2A receptors, we demonstrated that this 
facilitation is dependent on receptor coupling to Gq/11 subunits and subsequent PKC 
activation. As a consequence of their high degree of structural homology [25], 5-HT2A and 5-
HT2C receptors share their functional pharmacological profile in terms of the initiation of 
signalling cascades by coupling preferentially to Gq/11 proteins and successive activation of 
different phospholypases and intracellular calcium mobilisation pathways.  In the present 
study we have extended these investigations by examining whether a different Gq/11 coupled 
receptor emulates that effect observed with 5-HT2 receptor subtypes. Therefore, the 
muscarinic M3 acetylcholine receptor was chosen for this purpose based mainly on two 
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reasons; firstly, both M3 and MOP receptors are found in the same cellular population in 
native neural tissue, as is the case of adrenergic neurons from the locus coeruleous. Secondly, 
previous investigations performed in locus coeruleus neurons demonstrated a functional 
interaction between M3 and MOP endogenous receptors consisting in the increased acute 
desensitisation of the opioid receptor in response to morphine when PKC is activated either 
directly by phorbol esters or indirectly through M3 receptors [18, 19]. With that in mind, a 
Flp-InTM T-RExTM 293 cell line harbouring the gene encoding for FLAG-M3-Cerulean 
receptor in the inducible locus was generated. The pharmacological characterisation of this 
modified version of the human M3 receptor resulted in similar parameters to these previously 
described from studies conducted with the wild type receptor heterologously expressed in cell 
lines, either in terms of [3H]QNB constant affinity [26] or carbachol potency to generate 
inositol phosphate accumulation response [27].  Additionally, it was detected specific 
[3H]QNB binding sites together with functional carbachol responses in inositol phosphates 
and calcium mobilisation assays in the absence on FLAG-M3-Cerulean receptor expression 
corroborating, therefore, the endogenous expression of muscarinic acetylcholine receptors in 
HEK 293 cells already characterized as the M3 subtype [24].  
We formerly described that MOP-YFP receptors heterologously expressed in Flp-In T-REx 
HEK293 cells were functional in [35S]GTPγS binding assays [13] when stimulated with 
selective agonists such as DAMGO and morphine, presenting both agonists an equivalent 
potency and efficacy for MOP-YFP receptors in that functional assay. However, the main 
difference between both agonists was found after sustained stimulation of the receptors, i.e., 
whereas DAMGO pre-treatment of cells for a period up to 4 hours resulted in a significant 
lost of potency of this agonist in [35S]GTPγS binding assays, morphine was ineffective in 
promoting this desensitisation in parallel experiments. Nevertheless, the concomitant 
stimulation of serotonin 5-HT2A co-expressed with MOP-YFP receptors facilitated their 
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desensitisation by morphine after continued treatment. Equivalent results have been observed 
in relation to the loss of potency of morphine when FLAG-M3-Cerulean and MOP-YFP 
receptors were continuously activated concurrently with carbachol and morphine respectively. 
On the contrary, pre-treatment of cells with carbachol at different time points up to 4 hours 
was devoid of any significant effect on morphine potency in [35S]GTPγS binding assays 
excluding, therefore, an heterologous desensitisation of MOP-YFP receptors mediated by M3 
receptor activation. That lost of potency of morphine in [35S]GTPγS binding assays in 
samples from cells pre-treated with morphine plus carbachol was accompanied by a 
significant down regulation of MOP receptors determined by specific [3H]diprenorphine 
binding sites, particularly after 2 hours of pre-treatment. This result also emulates the effects 
observed earlier in equivalent experiments conducted with cells co-expressing 5-HT2A and 
MOP receptors [13].   
In relation to the facilitation of MOP-YFP receptor internalisation by morphine upon the 
concurrent activation of FLAG-M3-Cerulean receptors with carbachol, both epifluorescence 
microscopy experiments conducted with living cells and biotinylation protection assays 
evidenced the endocytosis of MOP receptors apparently at the same extent than the observed 
when using DAMGO as activating agonist. However, a detailed examination of both 
endocytosis processes performed by using an image analysis method recently described in our 
laboratory [14] revealed a significant difference between these two experimental situations in 
terms of the kinetics of the process. Morphine plus carbachol treatment mediated 
internalisation of MOP-YFP receptors is notably slower that the equivalent observed upon 
DAMGO treatment, suggesting a different molecular machinery behind these cellular events. 
With respect the quantification of endocytosis as a pharmacological response, the number of 
endosomes per cell obtained when using DAMGO as agonist was about twice the value 
resulted from equivalent treatments using morphine plus carbachol to activate M3 muscarinic 
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receptors endogenously expressed in Flp-In T-REx HEK293. Intriguingly, the expression of 
FLAG-M3-Cerulean receptors by doxycycline treatment promoted a substantial reduction of 
the endocytosis response evoked by DAMGO to a degree equivalent to the observed with 
morphine plus carbachol, being both responses comparable independently of the duration of 
the doxycycline treatment. The changes observed in the efficiency of the endocytosis response 
by DAMGO were not accompanied by a reduction in the velocity of the process since the 
kinetics of MOP-YFP internalisation remained unaffected throughout the different periods of 
doxycycline treatment. These results from quantitative endocystosis assays together with the 
fact that FLAG-M3-Cerulean receptor did not internalise either by stimulation with carbachol 
or in conjunction with MOP-YFP receptors, suggest a potential dominant negative effect of 
FLAG-M3-Cerulean over MOP-YFP receptors caused by protein-protein interactions that 
lead to the MOP-YFP receptor retention in the plasma membrane. Co-immunoprecipitation 
experiments demonstrated that FLAG-M3-Cerulean and MOP-YFP receptors form stable 
receptor heterocomplexes at the plasma membrane that are enriched through time, i.e., the 
longest is the period of doxycycline treatment the strongest is the co-immunoprecipitation 
signal obtained. This increase in the co-immunoprecipitation signal follows the increase of 
FLAG-M3-Cerulean receptor expression levels as visualised by Western blot analysis in 
equivalent periods of doxycycline treatment, suggesting a direct effect of the amount of 
FLAG-M3-Cerulean receptors in the formation of heteromers with MOP-YFP receptors. 
According to this result, one might assume that under longer periods of doxycycline induction 
the heteroreceptor complex is more consolidated and therefore, the potential effect on FLAG-
M3-Cerulean/MOP-YFP receptor trafficking more evident. Under these experimental 
conditions, i.e., 96 hours of receptor co-expression, the endocytosis of MOP-YFP receptors 
generated by DAMGO was not reduced in number of endosomes per cell in comparison with 
the one determined at 24 hours of doxycycline treatment. However, co-immunoprecipitation 
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experiments performed with cells treated with doxycycline for 96 hours and stimulated with 
DAMGO resulted in a substantial reduction in co-immunoprecipitated receptors with regards 
equivalent samples from cells not treated with agonist. Similarly, internalising MOP-YFP 
receptors are not accompanied by FLAG-M3-Cerulean receptors suggesting that a major 
fraction of the opioid receptor abandons the heterocomplex in the plasma membrane once 
they are conducted to the endocytic pathways. During the course of our investigations, the 
endocytosis of FLAG-M3-Cerulean receptor in response to carbachol in the Flp-In T-REx 
HEK293 expression system was not detected either by epifluorescence microscopy or 
biotinylation protection assays in cells treated with doxycycline for 24 hours. Similarly and 
under the same experimental conditions, stimulation of the co-expressed MOP-YFP receptor 
with either DAMGO or morphine resulted ineffective in facilitating the internalisation of 
FLAG-M3-Cerulean receptors. However, when cells were induced to express muscarinc 
receptors for up to 96 hours in order to allow the formation of detectable receptor heteromers, 
treatment of these cells with agonists for both receptors, i.e. DAMGO plus carbachol or 
morphine plus carbachol, resulted in the formation of detectable endocytic vesicles 
corresponding to FLAG-M3-Cerulean and MOP-YFP receptors in fluorescent microscopy 
images. Intriguingly, a meticulous co-localization analysis conducted by confocal microscopy 
imaging revealed that endosomes containing FLAG-M3-Cerulean and MOP-YFP receptors 
were segregated in different pools throughout cytoplasmic compartments, at difference of the 
plasma membrane where both receptors presented a higher degree of spatial coincidence. This 
result, together with the fact that the strongest interaction between both receptors is detected 
at this experimental condition, suggests that heteromeric complexes are essentially allocated 
in the plasma membrane and excludes a direct involvement of this receptor-receptor 
interaction in the occurrence of FLAG-M3-Cerulean receptor internalization. One possible 
explanation for this trafficking dissociation could be the inclusion in endosomes of those 
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receptors from the total population not engaged in heteromeric complexes. Actually, an 
important proportion of both receptors still remains at the plasma membrane when 
internalization of FLAG-M3-Cerulean and MOP-YFP receptors occurs. Otherwise, the 
reduction in co-immunoprecipitation signal when MOP-YFP is the only internalizing receptor 
could be indicative of a heteromer disruption upon the endocytosis initiated by agonist 
binding. Nevertheless, it seems to be necessary the prior formation of heteromeric complexes 
to get a substantial FLAG-M3-Cerulean receptor internalization.  
Our results described herein in relation to firstly, the effect of FLAG-M3-Cerulean and MOP-
YFP heteromerization on the opioid receptor trafficking and secondly, the divergence in the 
endosome sorting in these conditions when both receptors internalize, are indicative of the 
temporal and dynamic character of this receptor-receptor interaction. Results from previous 
studies that examined the effects of receptor heteromerization on MOP internalisation are 
discrepant and depending on the receptor partner considered for the investigation. In this 
sense, an initial research conducted on MOP-DOP heteromers concluded that both receptors 
endocytose separately, being the putative heterodimer only at the plasma membrane and 
suggesting, therefore, that MOP-DOP heteromers are contact dimers rather than domain 
swapping heterocomplexes [28]. However, a more recent study on the endocytic and 
postendocytic fate of MOP, DOP and MOP-DOP heteromers comes into contradiction with 
that previous one since they described that MOP receptor adopts novel trafficking properties 
in the context of MOP-DOP heterocomplexes [29]. Another circumstance where MOP 
receptors are internalising separately from its partner is the case of MOP-2AAR heteromer 
[30] where the interaction between both receptors was demonstrated by co-
immunoprecipitation experiments when co-expressed in HEK 293 cells and adrenaline and 
DAMGO treatments facilitated only the endocytosis of their corresponding receptors, i.e. 
2AAR and MOP respectively. On the other hand, it seems there is not a correlation between 
 29 
co-internalization and modified signalling in heteromers where one of the receptors is MOP, 
as is the case of MOP and 5-HT1A receptor interactions [31]; when both receptors are 
expressed in HEK 293 cells, the activation of 5-HT1A receptors do not co-internalize the co-
expressed MOP receptors and contrariwise. Moreover, there are also other circumstances 
where the interaction of MOP with other receptors led to modifications in the trafficking 
properties of any of the monomers. This is the case reported for the heteromerization of MOP 
and somatostatin sst2A receptors [32], the agonist stimulation of sst2A within the heteromer 
induced the internalisation of both receptors whereas DAMGO stimulation of MOP receptors 
in the heteromer promotes the phosphorylation and desensitization of both receptors but not 
the internalization of sst2A receptors. In a similar manner, the same group described that 
MOP and substance P NK1 receptor heteromerization did not change the ligand binding and 
signalling properties of these receptors, but it altered their internalization and resensitization 
profile [33]. Another case of asymmetric facilitation in the monomer internalization in 
heterocomplexes participated by MOP receptor is the one corresponding to MOP-mGluR5 
heteromers [34] where DAMGO treatments induced a significant co-internalization of MOP 
and mGluR5 in cells expressing both receptors. Overall and taking into account all these 
former observations already described where MOP receptor is part of heteroreceptor 
complexes, it seems that the stability of FLAG-M3-Cerulean/MOP-YFP receptor heteromers 
is a transient attribute rather than a permanent one and depends on the cellular localization 
and state of activation of both receptors. Whether FLAG-M3-Cerulean and MOP-YFP 
receptors interact with each other at the earlier stages of the biosynthetic pathways or once 
they reach the cell surface in their final mature form constitutes an issue not explored in our 
current investigations. However, confocal microscopy images point to the plasma membrane 
as the cell compartment where both receptors are primarily located. In addition, the different 
mode of expression followed for each protomer, i.e. inducible versus permanent, leads us to 
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conjecture that both receptors have higher chance to find to each other at the end of their 
synthesis and maturation than during the initial moments. This would further explain why 
robust signals after co-immunoprecipitation are obtained only after a longer period of 
expression of the M3 receptor, suggesting a possible gain of both heteromer stability and/or 
quantity following that period of receptor co-expression.  
We have previously shown using pharmacological inhibitors that PKC activation can directly 
regulate the endocytosis of MOP receptor by morphine facilitated by 5-HT2A receptor 
stimulation [13]. In relation to M3 muscarinic receptors, it has been reported a 
pharmacological interaction with MOP receptors in locus coeruleus consisting in the 
enhancement of MOP receptor desensitisation mediated by PKC [18, 19]. Actually, similar 
effects were achieved by the direct activation of PKC using phorbol esters bypassing 
therefore, the activation of M3 receptors. Additional studies in vivo and in vitro have also 
demonstrated that tolerance after chronic morphine treatment is attenuated or reversed when 
PKC inhibitors are co-administered [35]. In our present results we have not observed any type 
of facilitation of MOP-YFP receptor endocytosis promoted by morphine when activating 
directly PKC with a phorbol ester, in agreement with the observations from transgenic mice 
expressing FLAG-MOP receptors in locus coeruleus where activators of PKC had no 
significant roles in MOP receptor endocytosis [19]. Furthermore, in our experimental model, 
the endocytosis of MOP receptors by morphine facilitated by M3 receptor co-activation was 
not reverted by treatment with two different PKC inhibitors, which indicates potential 
differences between the molecular mechanisms underlying the facilitation mediated by 5-
HT2A with respect to M3 receptors. 
 
5. Conclusions 
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In the present report we demonstrate that the activation of M3 muscarinic receptors, which 
couples preferentially to Gq/11 proteins, facilitates the desensitisation, down-regulation and 
internalization of MOP receptors by morphine when both receptors are co-expressed in Flp-In 
T-REx HEK293 cells. Particularly, and in the case of the facilitation of MOP receptor 
endocytosis by morphine, this process is not dependent on the activation of PKC at difference 
of what was previously observed for 5-HT2A receptors. Fluorescence microscopy observations 
indicate that FLAG-M3-Cerulean and MOP-YFP receptors are mainly located in the plasma 
membrane where both receptors are prone to interact to each other constituting 
heterocomplexes. Furthermore, the formation of these heteromers seems to be dependent on 
time and the level of expression of FLAG-M3-Cerulean receptors. Although this protein-
protein interaction affects to some extent the endocytosis of MOP-YFP receptors in terms of 
the quantity of endosomes generated upon agonist activation, these heteromers are not present 
in endocytic vesicles when both receptors internalize either because the heteromer in the 
plasma membrane is disrupted or because a fraction of the total population of receptors not 
participating in the heteromer complex is the one that suffers internalization. Summarizing, 
M3 and MOP receptors present pharmacological interactions when co-expressed that are 
evidenced as alterations of some MOP receptor properties mediated by morphine binding. 
That pharmacological interaction is also accompanied by the formation of heteromers 
between both receptors with some consequences on MOP receptor trafficking. The dynamics 
associated to the stability of these receptor heterocomplexes in the plasma membrane might 
be indicative of the complexity of this type of protein-protein interaction. 
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Table 1 
Desensitization studies in cells co-expressing FLAG-M3-Cerulean and MOP-YFP 
receptors. 
Cells treated with doxycycline 24 hours prior the assay were incubated with morphine, 
carbachol or morphine plus carbachol at the specified concentrations during 30, 60, 120 and 
240 min. The different values correspond to the mean  SEM of the results obtained from a 
number of independent experiments as indicated in brackets. (pEC50): Two-way ANOVA on 
the effect of Pre-treatment F(2, 30) = 12.42 (P = 0.0001), Time F(4, 30) = 4.86 (P = 0.0038) and 
Pre-treatment/Time interaction F(8, 30) = 3.01 (P = 0.0132). *Dunnett´s Post-test comparing to 
not pre-treated P < 0.05. (Emax): Two-way ANOVA on the effect of Pre-treatment F(2, 30) = 
11.73 (P = 0.0002), Time F(4, 30) = 1.03 (P = 0.4071) and Pre-treatment/Time interaction F(8, 30) 
= 0.80 (P = 0.605). ¶Tukey´s Post-test comparing morphine and morphine plus carbachol 
treatments P < 0.05. 
 
Table 2 
Quantitative analysis of MOP-YFP receptor endocytosis by fluorescence microscopy in 
living cells. 
Cells were submitted to doxycycline treatment for different periods from 24 to 120 hours in 
order to co-express FLAG-M3-Cerulean and MOP-YFP receptors at different time lengths. 
Afterwards, cells were treated with either DAMGO or morphine + carbachol for 15 minutes 
and images were acquired by epifluorescence microscopy. Quantification of endocytosis was 
conducted by image analysis with Q-Endosomes algorithm (see Methods section). The 
different values correspond to the mean  SEM of the results obtained from a number of 
independent experiments as indicated in brackets. DAMGO treatment, (t1/2) One-way 
ANOVA P=0.6113. Morphine + carbachol treatment, (t1/2) One-way ANOVA P=0.5067. 
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DAMGO treatment, (Emax) One-way ANOVA P=0.0065. *Dunnett´s Post-Test P < 0.05. 
Morphine + carbachol treatment, (Emax) One-way ANOVA P=0.9453. ¶ t-test P < 0.05 when 
comparing DAMGO and morphine + carbachol groups within a particular doxycycline 
treatment time point. 
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Figure Legends 
Figure 1 
Generation of a Flp-In T-Rex 293 cell line harbouring FLAG-M3-Cerulean receptor in 
the inducible locus and permanently expressing MOP-YFP receptor. 
A: Epifluorescence microscopy imaging of cells treated with doxycycline at 10 ng.mL-1 for 
24 hours. CFP channel column corresponds to a microscopic field illuminated with light 
settings to make visible Cerulean protein and YFP channel column to the same field 
illuminated to visualize yellow fluorescent protein. + DOX and – DOX panels indicate cells 
treated and not treated with doxycycline, respectively. B: Representative immunoblots 
obtained with membranes from cells expressing FLAG-M3-Cerulean and MOP-YFP 
receptors treated at different concentrations of doxycycline for 24 hours, as indicated above 
each lane, and resolved with an anti-FLAG antibody (upper panel) or an anti-MOP receptor 
antibody (lower panel). 105 indicates protein size in KDa. The panel at the bottom represents 
a semi-logarithm graph displaying the signal optical density (O.D.) values corresponding to 
each doxycycline concentration from an immunoblot resolved with anti-FLAG antibody.  
 
Figure 2 
Time course of FLAG-M3-Cerulean receptor expression induced by doxycycline 
treatment. 
Representative immunoblots obtained with membranes from Flp-In T-Rex 293 cells 
expressing FLAG-M3-Cerulean and MOP-YFP receptors and treated with doxycycline at 10 
ng.mL-1 for different periods as indicated in hours above each lane. The top panel corresponds 
to a blot resolved with an anti-FLAG antibody whereas the bottom panel corresponds to the 
equivalent blot resolved with an anti-MOP antibody. 105 indicates protein size in KDa. 
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Figure 3 
Pharmacological expression of FLAG-M3-Cerulean and MOP-YFP receptors and 
functional characterization of FLAG-M3-Cerulean receptors. 
A: Graph plot displaying [3H]QNB specific binding from a saturation binding assay 
performed with membranes from cells induced with doxycycline for 24h to express FLAG-
M3-Cerulean receptors. B: Graph plot corresponding to [3H]diprenorphine specific binding 
from saturation binding assays performed with membranes from cells induced with 
doxycycline (filled symbols) and not treated with doxycycline (opened symbols). C: 
Carbachol dose-response curves displaying the generation of inositol 1,4,5-triphosphate (IP3) 
in cells induced with doxycycline for 24h to express FLAG-M3-Cerulean receptors (filled 
symbols) and not treated with doxycycline (opened symbols). D: Carbachol dose-response 
curves corresponding to calcium mobilization experiments with cells induced with 
doxycycline for 24h to express FLAG-M3-Cerulean receptors (filled symbols) and not treated 
with doxycycline (opened symbols).  
 
Figure 4 
Desensitisation and down-regulation studies on MOP-YFP receptors. 
[35S]GTPS binding assays in response to various concentrations of morphine with 
membranes from cells induced to express FLAG-M3-Cerulean receptors for 24 hours and 
treated with morphine at 10 M (A), carbachol at 1 mM (B), and morphine plus carbachol 
(C), for different periods as indicated in each graph. D: Variation of binding sites determined 
at a saturating concentration of [3H]diprenorphine in membranes from cells induced to 
express FLAG-M3-Cerulean receptors for 24 hours and treated with morphine (10 M) or 
morphine (10 M) plus carbachol (1mM) for different times. 
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Figure 5 
Internalization assays by fluorescence microscopy with living cells. 
Cells induced to express FLAG-M3-Cerulean receptors were treated with DAMGO (10 M), 
morphine (10 M), carbachol (1 mM) or a combination of morphine plus carbachol, and 
images were acquired every 3 min during 30 min. Pictures show images corresponding to the 
starting (00:00) and the end point (30:00) of the indicated agonist treatments from the same 
microscopic field illuminated to visualize MOP-YFP (MOP-YFP) or FLAG-M3-Cerulean 
(M3Cerulean) receptors. 
 
Figure 6 
Internalization studies by biotinylation protection assays. 
Cells induced to express FLAG-M3-Cerulean receptors were biotinylated and subsequently 
treated for 30 min with DAMGO (10 M), morphine (10 M), carbachol (1mM), DAMGO 
plus carbachol (DC), morphine plus carbachol (MC) or vehicle (NT). After agonist treatment 
and biotin cleavage, cell lysates were immunoprecipitated with streptavidin and processed by 
Western blot analysis. A: Image corresponding to a representative immunoblot resolved with 
an anti-FLAG antibody. Bar graph displays the mean  SEM of the optical density measured 
from immunoblots of at least three independent experiments compared to the intensity signal 
value obtained with not treated (NT) cells. One-way ANOVA, P = 0.1659. B: Image 
corresponding to a representative immunoblot resolved with an anti-MOP receptor antibody. 
Bar graph displays the mean  SEM of the optical density corresponding to the different 
experimental conditions measured from immunoblots corresponding to at least three 
independent experiments compared to the intensity signal value obtained with not treated 
(NT) cells. One-way ANOVA, P < 0.0001. * Dunnett´s post hoc test, P < 0.0001. In both 
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cases, 100 % corresponds to control cells biotinylated and not submitted to cleavage and 
STRIP to biotinylated cells not treated with agonist drugs and processed for biotin cleavage. 
 
Figure 7 
Analysis of the effect of direct activation of PKC on MOP-YFP receptor internalization 
by biotinylation protection assays. 
Biotinylated cells were treated with DAMGO (10 M), morphine (10 M), morphine plus 
PMA (0.1 M), morphine plus carbachol (1 mM) or vehicle (NT) for 30 min and 
subsequently submitted for biotin cleavage. Afterwards, cell lysates were immunoprecipitated 
with straptividine and samples processed by Western blot with an anti-MOP receptor 
antibody. Upper image shows a representative immunoblot where 100% corresponds to 
samples from cells biotinylated and submitted to neither cleavage nor agonist treatments, 
STRIP to biotinylated cells not treated with agonist drugs and processed for cleavage and + 
DOX indicates samples from cells treated with doxycycline for 24 h to induce the expression 
of FLAG-M3-Cerulean receptors. Lower bar graph represents the mean  SEM of the optical 
density corresponding to the different experimental conditions measured from immunoblots 
corresponding to at least three independent experiments and compared to the intensity signal 
value obtained with not treated (NT) cells. One-way ANOVA, P < 0.0001. * Dunnett´s post 
hoc test, P < 0.0001. 
 
Figure 8 
Effect of PKC direct activation or inhibition on MOP-YFP receptor internalization 
promoted by morphine. 
Epifluorescence microscopy images taken from living cells showing MOP-YFP receptors 
before (00:00) and after (30:00) 30 min of the following drug treatments: morphine (10 M) 
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plus PMA (0.1 M) (A), morphine plus carbachol (1 mM) in concurrence with Ro31-8220 
(0.1 M) (B) and morphine plus carbachol in concurrence with chelerytrine (1 M) (C). Cells 
were treated with doxycycline for 24h prior to the experiment. 
 
Figure 9 
Effect of FLAG-M3-Cerulean and MOP-YFP receptor heteromerization on the 
internalization promoted by agonist stimulation. 
A: Lysates from cells induced to express FLAG-M3-Cerulean receptors with doxycycline for 
different periods (24, 48, 72 and 96 h) were immunoprecipitated with an anti-MOP receptor 
antibody (MOP) and processed for Western blot analysis with anti-FLAG antibody 
(FLAG). Upper panel shows a representative immunoblot obtained with these samples. 
Lower panels correspond to immunoblots from cell lysates before immunprecipitation 
resolved with either anti-FLAG (FLAG) or anti-MOP (MOP) antibodies to monitor 
FLAG-M3-Cerulean and MOP-YFP receptor expression in these cells.  are samples from 
cells not treated with doxycycline. Protein sizes are indicated in KDa. B: Cells treated for 96 
h with doxycycline were treated with DAMGO (10 M) (D), DAMGO plus carbachol (1mM) 
(DC), morphine (10 M) plus carbachol (MC) or vehicle () for 30 min and subsequently 
cell lysates were immunoprecipitated with an anti-MOP receptor antibody and analysed by 
Western blot with anti-FLAG antibody (upper panel). Lower panels correspond to 
immunoblots resolved with either anti-FLAG or anti-MOP receptor antibodies to confirm the 
presence of FLAG-M3-Cerulean and MOP-YFP receptors in the original cell lysates. C: 
Epifluorescence microscopy images obtained from cells illuminated to simultaneously 
visualize FLAG-M3-Cerulean and MOP-YFP receptors (M3Cerulean and MOPYFP 
respectively) after 30 min of treatment with DAMGO (10 M), DAMGO plus carbachol 
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(1mM), morphine (10 M) plus carbachol or vehicle (). Cells were treated with doxycycline 
for 96h prior to the experiment. 
 
Figure 10 
Analysis of the subcellular co-localization of FLAG-M3-Cerulean and MOP-YFP 
receptors. 
Fluorescence confocal microscopy images corresponding to cells from the same microscopic 
field treated with doxycycline for 24h or 96h and showing both FLAG-M3-Cerulean receptors 
(left column) and MOP-YFP receptors (middle column). Prior to image acquisition, cells were 
treated for 30 min with DAMGO plus carbachol (1mM) (DC), morphine (10 M) plus 
carbachol (MC) or vehicle (). Yellow frames in each picture indicate these selected areas 
corresponding to either plasma membrane (pm) or cytosolic regions (c) where co-localization 
image analysis was performed. Right column panels show in detail merged FLAG-M3-
Cerulean (red) and MOP-YFP (green) images corresponding to the different selected areas. 
Overlapping Pearson´s correlation coefficient (r) determined in each case is indicated at the 
bottom of each panel. 
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Table 1.
Not pre-treated 30 min 60 min 120 min 240 min Pre-treatment
pEC50 7.62 ± 0.05 (3) 7.64 ± 0.01 (3) 7.55 ± 0.02 (3) 7.58 ± 0.09 (3) 7.51 ± 0.10 (3) Morphine 10 μM
7.80 ± 0.02 (3) 7.59 ± 0.12 (3) 7.66 ± 0.02 (3) 7.66 ± 0.13 (3) 7.82 ± 0.15 (3) Carbachol 1 mM
7.88 ± 0.03 (3) 7.48 ± 0.03 (3)* 7.28 ± 0.06 (3)* 7.24 ± 0.15 (3)* 7.24 ± 0.13 (3)* Morphine 10 μM
Carbachol 1 mM
% Not pre-treated Emax 100 (3) 103.68 ± 1.63 (3) 100.51 ± 2.70 (3) 106.83 ± 7.39 (3) 105.73 ± 5.67 (3) Morphine 10 μM
100 (3) 101.32 ± 8.76 (3) 97.04 ± 1.79 (3) 105.43 ± 0.79 (3) 107.55 ± 6.40 (3) Carbachol 1 mM
100 (3) 73.47 ± 10.13 (3) 69.33 ± 9.06 (3) 84.82 ± 18.36 (3) 80.40 ± 14.84 (3) Morphine 10 μM
Carbachol 1 mM
Table 2.
Doxycycline treatment (hours) Not treated 24 48 72 96 120 Agonists
t1/2 (min) 4.40 ± 0.32 (3) 5.07 ± 0.21 (3) 4.47 ± 0.44 (3) 4.55 ± 0.29 (3) 4.68 ± 0.52 (3) 5.40 ± 0.75 (3) DAMGO 10 μM
7.72 ± 0.69 (3) 7.98 ± 0.97 (3) 7.03 ± 0.34 (3) 8.12 ± 0.69 (3) 8.60 ± 0.60 (3) 8.99 ± 0.85 (3) Morphine 
10 μM
Carbachol
1 mM
Emax (no. vesicles/cell) 35.11 ± 3.88 (3) 22.34 ± 2.37 (3)* 16.84 ± 2.11 (3)* 18.50 ± 3.88 (3)* 17.58 ± 1.81 (3)* 19.84 ± 2.46 (3)* DAMGO 10 μM
17.82 ± 2.79 (3) 15.75 ± 2.74 (3) 13.11 ± 1.06 (3) 15.79 ± 3.80 (3) 14.15 ± 3.78 (3) 15.24 ± 4.92 (3) Morphine 
10 μM
Carbachol
1 mM
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